ACMG-guided germline variant classification for hereditary cancer panels, exomes, and genomes: from BRCA1/2 to multi-gene panels to germline reflex in oncology programs.
Hereditary cancer testing has expanded well beyond BRCA1 and BRCA2. Clinical labs now run multi-gene panels covering dozens of high- and moderate-penetrance genes: PALB2, ATM, CHEK2, CDH1, RAD51C, MLH1, MSH2, MSH6, PMS2, and others, across a range of assay types from targeted panels to clinical exomes. Each gene carries its own evidence base, penetrance data, and classification nuance under the ACMG/AMP framework.
At the same time, the boundary between hereditary cancer testing and oncology testing is narrowing. Labs running somatic tumor panels increasingly add germline reflex workflows when a tumor variant raises the possibility of inherited risk. Genetic counseling programs integrate family history and cascade testing into their variant interpretation process. Hereditary cancer software needs to be flexible enough to support multiple workflows, not just the classic standalone hereditary panel.
VarSeq handles this range. Whether the program is a high-throughput hereditary panel lab, an oncology lab adding germline reflex capability, or a clinical genetics program working with family pedigrees and risk stratification, the same platform handles annotation, ACMG classification, CNV detection, and clinical reporting. The companion germline analysis guide covers the inheritance and classification principles that underpin these workflows.
A hereditary cancer program runs under CLIA certification, applies the ACMG/AMP standard consistently, and documents every interpretation. Four capabilities carry the workflow.
The ACMG/AMP five-tier variant classification framework is the clinical standard for germline variant interpretation. Applied consistently across a high-volume panel program, it requires automation, not because the criteria are simple, but because manual application introduces inter-interpreter variability that undermines reporting consistency and complicates CLIA validation.
VSClinical applies ACMG criteria for each variant and pre-populates the classification with the supporting evidence used for every criterion. Pathologists and genetic counselors review, accept, or override before sign-out, and every decision is logged. For a full treatment of the 28 ACMG criteria, see genome interpretation.
Multi-exon deletions and duplications are clinically significant in several hereditary cancer genes, including the BRCA1 exon 13 deletion and APC large deletions, yet standard SNV/indel callers miss them. Detecting these historically required a separate MLPA assay.
VarSeq detects multi-exon CNVs directly from panel sequencing data, removing the need for orthogonal testing in most cases and delivering CNV results in the same analysis session as small variant results. See CNV and structural variant analysis for the detection method.
Hereditary cancer programs run a range of assay types: focused BRCA1/2 panels, comprehensive 50+ gene panels, clinical exomes, and whole genomes used in national screening contexts. The software needs to handle all of these without separate pipelines.
VarSeq supports targeted gene panels, clinical exomes, and genomes through the same annotation and classification framework, with assay-specific filtering configurations.
Germline findings have implications beyond the proband. Pathogenic variants in BRCA1/2, Lynch syndrome genes, and other hereditary cancer genes trigger cascade testing for first-degree relatives.
VarSeq supports family history integration and pedigree data within the variant interpretation process, helping labs and genetic counseling programs document familial risk context and streamline the identification of relatives who require targeted testing.
One platform covers standalone panels, germline reflex in oncology, genetic counseling programs, and exome- or genome-based hereditary testing.
High-throughput analysis of targeted multi-gene panels: BRCA1/2, Lynch syndrome (MLH1/MSH2/MSH6/PMS2), and expanded panels covering moderate-penetrance genes (PALB2, ATM, CHEK2, CDH1, RAD51C, NBN). ACMG auto-classification, integrated CNV detection, and structured clinical reporting in a single workflow.
When somatic tumor profiling identifies a variant with possible germline origin, such as BRCA1/2 in an ovarian or breast tumor, MLH1 in colorectal, or TP53 in Li-Fraumeni, the same platform applies ACMG criteria to the germline confirmation sample. No workflow change, no separate tool. The somatic variant analysis page covers the tumor side of this in full.
Family history integration, pedigree-based risk context, and cascade testing support for programs where the clinical geneticist or genetic counselor is central to the interpretation workflow. Classification consistency and audit trail documentation support variant classification committee review.
For programs using clinical exomes or whole genomes as the primary hereditary cancer assay, increasingly common in pediatric oncology and national cancer screening contexts, VarSeq applies the same ACMG framework with gene-panel-style filtering to focus interpretation on the relevant hereditary cancer gene set.
The gap between tumor profiling and germline risk is narrowing. Many oncology labs now add germline reflex testing when a somatic variant suggests a possible inherited risk. VarSeq maintains distinct classification catalogs for somatic (AMP) and germline (ACMG) findings, so the two evidence frameworks stay separate within one program.
Move from identified tumor drivers to germline confirmation using the same platform and institutional knowledgebase.
Apply AMP guidelines for somatic actionability and ACMG criteria for germline pathogenicity inside a single clinical environment.
Identify variant in tumor tissue. Assess for therapy matching under AMP guidelines.
Confirm variant in blood or normal tissue. Assess for hereditary risk under ACMG criteria.
Finalize a report covering both tumor drivers and familial cancer susceptibility.
VarSeq supports hereditary cancer variant interpretation across the full range of high- and moderate-penetrance hereditary cancer genes. Representative coverage includes:
| Syndrome | Key Genes | Assay Types Supported |
|---|---|---|
| Hereditary Breast and Ovarian Cancer (HBOC) | BRCA1, BRCA2, PALB2, RAD51C, RAD51D | Panel, Exome, Genome |
| Lynch Syndrome | MLH1, MSH2, MSH6, PMS2, EPCAM | Panel, Exome, Genome |
| Li-Fraumeni Syndrome | TP53 | Panel, Exome, Genome |
| Hereditary Diffuse Gastric Cancer | CDH1 | Panel, Exome |
| Cowden Syndrome | PTEN | Panel, Exome |
| Familial Adenomatous Polyposis | APC | Panel, Exome |
| Moderate-Penetrance Breast Cancer Risk | ATM, CHEK2, NF1, NBN | Panel, Exome |
This is representative, not exhaustive. VarSeq's annotation and classification framework applies to any gene with an established hereditary cancer evidence base in ClinVar, ClinGen gene-disease validity classifications, and associated literature databases.
Hereditary cancer programs operate under CLIA certification and, depending on jurisdiction, additional regulatory frameworks. Golden Helix supports three deployment models so labs can match institutional data governance requirements. Review the full security and compliance capabilities for details.
Full deployment within the institution's own infrastructure. Patient data stays inside the institutional boundary, keeping HIPAA-regulated data within the lab's controlled environment.
Deployment within the lab's own AWS or Azure environment. Full administrative control, geographic data residency selection, and elastic compute scaling for variable sample volumes.
Fully offline deployment for the most sensitive environments. All software, annotation databases, and licensing operate on an isolated internal network.
Quality system. Golden Helix operates under an ISO 13485-certified Quality Management System. VarSeq's deterministic pipeline supports reproducibility documentation for programs running under ISO 15189 or CAP accreditation, and all releases are version-controlled with change documentation designed for laboratory QMS integration and CLIA inspection readiness.
Hereditary cancer software: gene coverage, CNV detection, ACMG classification, germline reflex, and deployment.
VarSeq supports variant annotation and ACMG classification for the full range of clinically established hereditary cancer genes, including BRCA1, BRCA2, PALB2, ATM, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, TP53, CDH1, PTEN, APC, RAD51C, RAD51D, and others. The annotation framework draws on ClinVar, ClinGen gene-disease validity classifications, gnomAD, and integrated literature databases including Mastermind (Genomenon). Any gene with an established hereditary cancer evidence base in these databases is supported.
The platform is not limited to a fixed gene list. Labs configure their own panel gene sets and filtering criteria.
Integrated CNV detection is built into VarSeq for panel, exome, and genome data. Multi-exon deletions and duplications, clinically significant in BRCA1/2, APC, MLH1, and other hereditary cancer genes, are detected directly from the panel sequencing data, within the same analysis session as SNV and indel calling. This removes the need for MLPA in most cases, reducing per-sample cost and turnaround time.
Labs can configure CNV detection sensitivity thresholds to match their assay and validation requirements.
VSClinical applies the ACMG/AMP 28-criterion framework for each variant, evaluating population frequency (gnomAD, ExAC), functional evidence (ClinVar, literature), computational predictors, segregation data, and de novo evidence where available. The classifier produces a preliminary five-tier classification, Pathogenic, Likely Pathogenic, Variant of Uncertain Significance, Likely Benign, or Benign, with the evidence used for each criterion displayed for review.
The interpreting pathologist or genetic counselor reviews the pre-classification and either accepts or overrides it before sign-out. All decisions are logged with a timestamp and user identifier, supporting audit trail requirements under CLIA.
Yes. When somatic tumor profiling identifies a variant with possible germline origin, such as BRCA1/2 in ovarian or breast cancer, mismatch repair genes in colorectal cancer, or TP53 in pediatric cases, the same VarSeq platform applies ACMG classification criteria to the germline confirmation sample. Labs do not need a separate tool or workflow for the germline component.
VarSeq maintains distinct classification catalogs for somatic (AMP) and germline (ACMG) findings, so the two evidence frameworks do not interfere with each other within the same program.
All three. VarSeq supports targeted hereditary cancer panels, clinical exomes, and whole genomes through the same annotation and classification framework. For exome and genome data, labs apply gene-panel-style filtering to focus interpretation on the hereditary cancer gene set relevant to their clinical indication.
This is increasingly common in pediatric oncology programs and national hereditary cancer screening initiatives where exome or genome sequencing is the primary assay rather than a targeted panel.
VarSeq supports pedigree data integration and family history documentation within the variant interpretation workflow. For a proband with a pathogenic or likely pathogenic hereditary cancer finding, the platform supports documentation of family history context and the generation of targeted variant reports for cascade testing of first-degree relatives.
Genetic counseling programs can use VSWarehouse to store classification history and retrieve prior interpretations of familial variants rapidly across samples and time.
On-premises, private cloud, and air-gapped configurations are all supported. For hereditary cancer programs handling patient data under HIPAA and institutional data governance requirements, on-premises or private cloud deployment keeps all patient data within the lab's controlled environment.
All deployment modes support the full VarSeq and VSClinical ACMG feature set. See security and compliance for full details.
Explore featured articles and expert-led webcasts on hereditary cancer testing and germline variant interpretation.
Labs running hereditary cancer panels, exomes, or germline reflex programs use VarSeq to standardize ACMG classification, eliminate separate CNV assays, and deliver audit-ready reports.